Great Lakes Advisors LLC Purchases New Position in Edwards Lifesciences Corporation $EW

Great Lakes Advisors LLC acquired a new position in Edwards Lifesciences Corporation (NYSE:EW) in the 2nd quarter, HoldingsChannel.com reports. The fund acquired 13,877 shares of the medical research company’s stock, valued at approximately $1,255,000.

A number of other hedge funds have also bought and sold shares of the business. Rehmann Capital Advisory Group raised its holdings in Edwards Lifesciences by 2.1% during the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock valued at $546,000 after acquiring an additional 130 shares during the period. McIlrath & Eck LLC boosted its holdings in shares of Edwards Lifesciences by 14.6% in the fourth quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company’s stock worth $90,000 after acquiring an additional 135 shares during the period. Quadrant Capital Group LLC boosted its holdings in shares of Edwards Lifesciences by 0.9% in the fourth quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company’s stock worth $1,288,000 after acquiring an additional 136 shares during the period. Stephens Inc. AR grew its position in shares of Edwards Lifesciences by 5.4% in the fourth quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company’s stock valued at $239,000 after purchasing an additional 144 shares in the last quarter. Finally, Composition Wealth LLC grew its position in shares of Edwards Lifesciences by 1.6% in the fourth quarter. Composition Wealth LLC now owns 9,331 shares of the medical research company’s stock valued at $795,000 after purchasing an additional 147 shares in the last quarter. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares in the company, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president directly owned 98,611 shares of the company’s stock, valued at $8,521,962.62. The trade was a 19.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 25,570 shares of company stock worth $2,219,390. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Trading Up 0.1%

Shares of EW stock opened at $89.89 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The company has a market capitalization of $51.76 billion, a PE ratio of 51.66, a price-to-earnings-growth ratio of 2.26 and a beta of 0.85. The business’s fifty day moving average is $89.21 and its 200 day moving average is $84.67.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same quarter last year, the company earned $0.67 earnings per share. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Analysts Set New Price Targets

EW has been the topic of a number of recent research reports. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Barclays reaffirmed an “overweight” rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Citigroup upped their price target on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Finally, Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Seventeen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.